As an expert in business development, Georg enriches our team at Dynamic42. With his creative approach and many years of experience in medical technology and project management, Georg is a valuable addition to our team.
Organ-on-Chip technology (OoC) has the potential to shape the future of drug research. It allows the simulation of human organs on a chip, enabling more reliable tests for drug development.
Summary of our work that established a human liver microphysiological model as an in vitro platform for the evaluation of drug-induced liver injury, published in Nature Scientific Reports. This case study sheds light on the effects of the known hepatotoxic antibiotic trovafloxacin and the commonly used analog levofloxacin on human liver tissue, using an innovative chip-based liver model.
Lately Thomas Sommermann joined Dynamic42. Thomas is an experienced scientist in the field of immunology and shares our vision regarding the enormous potential of the organ-on-chip technology.
In April, our CEO Martin Raasch and our scientists Anne-Katrin Bothe and Tim Kaden attended the 3D Cell Culture Conference in Freiburg.
Dynamic42 is one of the chosen companies and research groups receiving funding from of the Sanofi iDEA-iTECH Award.
Dynamic42 GmbH is celebrating its fifth anniversary this spring. The last few years have been characterised by continuous growth, professionalisation and forward-looking innovations.
Science is our passion. That's why we invest in the next generation of scientists. Meet our Master's students Sophie and Daria.
With the help of organ models, we are already increasing drug safety and advancing approaches for individualized medicine.
Meet our Lab Manager Katja Graf: I am proud to be involved in developing and commercializing a pioneering technology such as organ-on-chip.